Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Dec;102(24):10393-10408.
doi: 10.1007/s00253-018-9420-8. Epub 2018 Oct 18.

Bacteriocins: Perspective for the Development of Novel Anticancer Drugs

Affiliations
Review

Bacteriocins: Perspective for the Development of Novel Anticancer Drugs

Piyush Baindara et al. Appl Microbiol Biotechnol. .

Abstract

Antimicrobial peptides (AMPs) from prokaryotic source also known as bacteriocins are ribosomally synthesized by bacteria belonging to different eubacterial taxonomic branches. Most of these AMPs are low molecular weight cationic membrane active peptides that disrupt membrane by forming pores in target cell membranes resulting in cell death. While these peptides known to exhibit broad-spectrum antimicrobial activity, including antibacterial and antifungal, they displayed minimal cytotoxicity to the host cells. Their antimicrobial efficacy has been demonstrated in vivo using diverse animal infection models. Therefore, we have discussed some of the promising peptides for their ability towards potential therapeutic applications. Further, some of these bacteriocins have also been reported to exhibit significant biological activity against various types of cancer cells in different experimental studies. In fact, differential cytotoxicity towards cancer cells as compared to normal cells by certain bacteriocins directs for a much focused research to utilize these compounds as novel therapeutic agents. In this review, bacteriocins that demonstrated antitumor activity against diverse cancer cell lines have been discussed emphasizing their biochemical features, selectivity against extra targets and molecular mechanisms of action.

Keywords: Anticancer; Antimicrobial peptides; Bacteriocin; Cationic; Cell lines; Lantibiotic.

Similar articles

See all similar articles

Cited by 7 articles

See all "Cited by" articles

LinkOut - more resources

Feedback